These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23855143)

  • 1. Choice of erythropoiesis stimulating agent in ESRD.
    Fishbane S; Shah HH
    Nephrol News Issues; 2013 Jun; 27(7):Supp 10-2. PubMed ID: 23855143
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel erythropoiesis-stimulating agents: a new era in anemia management.
    Macdougall IC
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):200-7. PubMed ID: 18077782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new label for erythropoiesis stimulating agents: the FDA'S sentence.
    Fishbane S; Jhaveri KD
    Semin Dial; 2012 May; 25(3):263-6. PubMed ID: 22515844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoiesis-stimulating agents in kidney and cardiac disease.
    Fluck R
    Br J Hosp Med (Lond); 2006 Oct; 67(10):533-7. PubMed ID: 17069130
    [No Abstract]   [Full Text] [Related]  

  • 6. Erythropoiesis-stimulating agents for the management of anemia of chronic kidney disease: past advancements and current innovations.
    Dutka P
    Nephrol Nurs J; 2012; 39(6):447-57. PubMed ID: 23469411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating anemia with erythropoiesis-stimulating agents: effects on quality of life.
    Moossavi S; Freedman BI
    Arch Intern Med; 2009 Jun; 169(12):1100-1. PubMed ID: 19546408
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel erythropoiesis-stimulating protein in the management of the anemia of chronic renal failure.
    Maxwell AP
    Kidney Int; 2002 Aug; 62(2):720-9. PubMed ID: 12110039
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacological and clinical profiles of long-lasting erythropoiesis-stimulating agent (darbepoetin alfa; NESP].
    Nagano N
    Nihon Yakurigaku Zasshi; 2008 Apr; 131(4):291-9. PubMed ID: 18408341
    [No Abstract]   [Full Text] [Related]  

  • 10. CERA: third-generation erythropoiesis-stimulating agent.
    Topf JM
    Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
    Eschbach JW; Haley NR; Adamson JW
    Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841
    [No Abstract]   [Full Text] [Related]  

  • 12. The TREAT study answers a question, not the question.
    Coyne DW
    Am J Kidney Dis; 2008 Sep; 52(3):626-7; author reply 627-8. PubMed ID: 18725019
    [No Abstract]   [Full Text] [Related]  

  • 13. Changing patterns of anemia management in US hemodialysis patients.
    Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA
    Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finding a rational approach to ESA therapy--for payers and patients.
    Messana A
    Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
    [No Abstract]   [Full Text] [Related]  

  • 15. [Erythropoiesis stimulating agents in clinical practice].
    Niemczyk L; Dębowska M
    Wiad Lek; 2014; 67(3):413-5. PubMed ID: 25782201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia].
    Nikolaev AIu; Klepikov PV; Lashutin SV
    Ter Arkh; 1992; 64(6):90-1. PubMed ID: 1440349
    [No Abstract]   [Full Text] [Related]  

  • 17. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
    Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.
    Molina M; Navarro MJ; de Gracia C; Alvarez G; de Alarcon R; Garcia MA
    Ren Fail; 2008; 30(8):778-83. PubMed ID: 18791951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do pentoxifylline and ascorbic acid improve erythropoiesis stimulating agent resistance?
    Rho M
    Semin Dial; 2011; 24(4):378-9. PubMed ID: 21801213
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to "effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia".
    Coiffier B
    Oncologist; 2005 Oct; 10(9):762-3; author reply 764-5. PubMed ID: 16249359
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.